Plain-English translation of NCT06387056 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether —combined with different partner drugs chosen based on your tumor's genetic profile—can help shrink advanced prostate cancer before surgery. The study divides patients into four groups based on genetic testing results, and each group receives a tailored combination of medications designed to target their specific cancer type.
Prostate cancers vary genetically, and not all patients respond to the same treatment. This trial explores whether using genetic testing to personalize your drug combination—rather than giving everyone the same treatment—might work better and help more men with advanced disease.
You likely qualify if…
You likely don't qualify if…
First, you will undergo genetic testing of your cancer to determine which of four treatment groups you belong to. You will then receive several months of the medication combination tailored to your genetic profile, with regular doctor visits to monitor your response using imaging scans. If you respond well, you will proceed to surgery to remove your prostate and surrounding lymph nodes. After surgery, doctors will continue to follow you to track your cancer status and any long-term side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China